Psychedelics
Cybin Lands Key U.S. Patent for DMT Compounds
Preliminary DMT therapy data will guide the decision to initiate a phase 2 trial in the U.S. in early 2024.
The post Cybin Lands Key U.S. Patent for DMT…
Cybin Inc. (NYSE: CYBN) (NEO: CYBN) successfully obtained a U.S. patent for the compounds it uses in pre-clinical deuterated tryptamine research. The patent, No. 11,746,088, is valid until 2041.
Preliminary data from the trials on deuterated dimethyltryptamine (dDMT) are anticipated by the end of 2023. The data will guide the decision to initiate a phase 2 trial in the U.S. in early 2024, focusing on the potential therapeutic benefits of dDMT.
In a statement, Cybin CEO Doug Drysdale touted the company’s plans to merge with short-duration psychedelic therapy developer, Small Pharma.
“The strong synergy of our collective intellectual property provides an unparalleled opportunity to develop novel, differentiated therapeutics for patients in need of improved treatment options,” he said.
“Looking towards the next chapter for the combined company, this new composition of matter patent will have an important role in protecting the continued advancement of our development pipeline.”
Additionally, the company said it aims to disclose results for its study on CYB003, a synthetic form of psilocybin, for major depressive disorder and the CYB004-E study in the same timeframe.
Previous tests of CYB003, involving doses up to 12 milligrams, have reportedly shown it to be well-tolerated, with the company noting no serious side effects in their recent patient testing.
After these data releases, the company intends to present its research to the U.S. Food and Drug Administration. A phase 3 study of CYB003 is in the planning stages for a potential 2024 start.
The post Cybin Lands Key U.S. Patent for DMT Compounds appeared first on Green Market Report.
therapeutics
pharma
psilocybin
dmt
dimethyltryptamine
psychedelic
therapy
major depressive disorder
depressive disorder
Psychedelic Search Trends in 2023
Take a look at this 2023 search volume chart. Do you think you can guess what’s happening? I was pretty shocked when I noticed this spike for December…
Here Are the Champions! Our Top Performing Stories in 2023
It has been quite a year – not just for the psychedelic industry, but also for humanity as a whole. Volatile might not be the most elegant word for it,…
Psilocybin shows promise for treating eating disorders, but more controlled research is needed
Recent psychedelic research shows promising results for mental illnesses and eating disorders, with surveys and reports indicating psilocybin-assisted…
